KYMR

Kymera Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↓ 0/10
  • Momentum↑ 9/10
Kymera Therapeutics sales and earnings growth
KYMR Growth
Low
  • Revenue Y/Y↓ -50.05%
  • EPS Y/Y↓ -53.85%
  • FCF Y/Y↓ -55.34%
Kymera Therapeutics gross and profit margin trends
KYMR Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -674.80%
  • ROIC↓ -33.60%
Kymera Therapeutics net debt vs free cash flow
KYMR Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -874.7

Kymera Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗